We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Cites Indian Drugmaker for Sterility, Testing Issues
FDA Cites Indian Drugmaker for Sterility, Testing Issues
The FDA flagged a Shilpa Medicare facility in Telangana, India for numerous violations including noncompliant labeling, sterility procedures and testing methods.